Biomarkers to diagnose neurodegenerative disorders early in their course and to monitor responses of patients to therapeutic interventions are urgently needed to optimize the development and application of novel disease-modifying drugs. Trojanowski and colleagues discuss progress and key issues in the discovery and validation of such biomarkers, with a focus on Alzheimer's disease.
- Leslie M. Shaw
- Magdalena Korecka
- John Q. Trojanowski
